Illumina, Inc. (NASDAQ:ILMN) Receives Consensus Recommendation of “Buy” from Analysts

Shares of Illumina, Inc. (NASDAQ:ILMN) have received an average rating of “Buy” from the seventeen brokerages that are currently covering the firm, Marketbeat reports. One equities research analyst has rated the stock with a sell recommendation, two have issued a hold recommendation and fourteen have assigned a buy recommendation to the company. The average 12-month target price among brokerages that have issued ratings on the stock in the last year is $341.15.

ILMN has been the topic of several analyst reports. Zacks Investment Research lowered shares of GasLog Partners LP Unit from a “hold” rating to a “strong sell” rating in a report on Tuesday, April 2nd. BidaskClub lowered shares of Weyco Group from a “sell” rating to a “strong sell” rating in a report on Saturday. Cowen increased their target price on shares of Solaredge Technologies from $65.00 to $74.00 and gave the stock an “outperform” rating in a report on Friday. OTR Global lowered shares of Illumina to a “positive” rating in a report on Tuesday, April 2nd. Finally, Deutsche Bank increased their target price on shares of Spirit Airlines from $75.00 to $79.00 and gave the stock a “buy” rating in a report on Friday.

In related news, Director Jay T. Flatley sold 3,300 shares of the firm’s stock in a transaction on Wednesday, July 10th. The shares were sold at an average price of $376.50, for a total transaction of $1,242,450.00. Following the sale, the director now directly owns 272,616 shares in the company, valued at $102,639,924. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, SVP Charles Dadswell sold 124 shares of the firm’s stock in a transaction on Wednesday, May 1st. The stock was sold at an average price of $311.77, for a total transaction of $38,659.48. Following the sale, the senior vice president now owns 8,086 shares in the company, valued at $2,520,972.22. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 59,291 shares of company stock worth $19,459,234. 0.38% of the stock is currently owned by company insiders.

Large investors have recently modified their holdings of the stock. Strategy Asset Managers LLC acquired a new stake in Illumina in the 1st quarter valued at $26,000. Massmutual Trust Co. FSB ADV increased its stake in Illumina by 83.0% in the 4th quarter. Massmutual Trust Co. FSB ADV now owns 86 shares of the life sciences company’s stock valued at $26,000 after buying an additional 39 shares during the last quarter. C J Advisory Inc acquired a new stake in Illumina in the 1st quarter valued at $29,000. Lake Point Wealth Management acquired a new stake in Illumina in the 4th quarter valued at $30,000. Finally, Sontag Advisory LLC acquired a new stake in Illumina in the 4th quarter valued at $34,000. Institutional investors and hedge funds own 89.69% of the company’s stock.

ILMN stock traded down $58.61 during midday trading on Friday, reaching $305.05. The company’s stock had a trading volume of 8,474,211 shares, compared to its average volume of 880,816. Illumina has a 52 week low of $268.62 and a 52 week high of $380.76. The stock has a market capitalization of $53.46 billion, a PE ratio of 53.33, a PEG ratio of 2.53 and a beta of 1.15. The company has a debt-to-equity ratio of 0.27, a quick ratio of 3.33 and a current ratio of 3.66. The stock’s 50-day moving average price is $344.09.

Illumina (NASDAQ:ILMN) last announced its quarterly earnings data on Thursday, April 25th. The life sciences company reported $1.60 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.34 by $0.26. Illumina had a net margin of 25.06% and a return on equity of 23.49%. The firm had revenue of $846.00 million for the quarter, compared to analysts’ expectations of $838.70 million. During the same period last year, the firm earned $1.45 earnings per share. The business’s revenue for the quarter was up 8.2% on a year-over-year basis. Analysts predict that Illumina will post 6.68 earnings per share for the current year.

About Illumina

Illumina, Inc provides sequencing and array-based solutions for genetic analysis. The company operates in two segments, Core Illumina and Consolidated VIEs. It offers sequencing that provides researchers with various applications and the ability to sequence mammalian genomes; and arrays for a range of deoxyribonucleic acid and RNA analysis applications, including single nucleotide polymorphism genotyping, copy number variations analysis, gene expression analysis, and methylation analysis, as well as enables the detection of known genetic markers on a single array.

Read More: What is a trade deficit?

Analyst Recommendations for Illumina (NASDAQ:ILMN)

Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.